Degirmencioglu, S. Et Al. 2019. A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG). JOURNAL OF BUON , vol.24, no.1 , 242-248.

Degirmencioglu, S., Tanriverdi, O., Menekse, S., Dogan, M., Hacioglu, B., Oktay, E., ... Erdem, D.(2019). A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG). JOURNAL OF BUON , vol.24, no.1, 242-248.

Degirmencioglu, Serkan Et Al. "A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)," JOURNAL OF BUON , vol.24, no.1, 242-248, 2019

Degirmencioglu, Serkan Et Al. "A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)." JOURNAL OF BUON , vol.24, no.1, pp.242-248, 2019

Degirmencioglu, S. Et Al. (2019) . "A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)." JOURNAL OF BUON , vol.24, no.1, pp.242-248.

@article{article, author={Serkan Degirmencioglu Et Al. }, title={A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)}, journal={JOURNAL OF BUON}, year=2019, pages={242-248} }